BANK VONTOBEL/CALL/NOVO NORDISK ADR B/170/0.1/17.01.25 | Delayed Deutsche Boerse AG 10:52:32 2024-05-20 EDT | ||
| 0.41 EUR | 0.00% |
|
| Current month | -10.87% | ||
| 1 month | +2.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 0.41 | 0.00% |
| 24-05-17 | 0.41 | -6.82% |
| 24-05-16 | 0.44 | -6.38% |
| 24-05-15 | 0.47 | +6.82% |
| 24-05-14 | 0.44 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 10:52 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM9QFX |
| ISIN | DE000VM9QFX6 |
| Date issued | 2024-02-05 |
| Strike | 170 $ |
| Maturity | 2025-01-17 (242 Days) |
| Parity | 10 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.87 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.01 € |
| Spread % | 2.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
